Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study

August 27, 2021
─

MYINFLA™ 0.5 mg has been approved by Health Canada for the reduction of cardiovascular risk in patients with coronary disease

People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

Led by Dr. Jean-Claude Tardif, the COLCOT clinical trial compared colchicine to a placebo, as a complement to standard therapy, for the prevention of ischemic cardiovascular events in patients having recently experienced a myocardial infarction (also known as a heart attack).

Published in the prestigious New England Journal of Medicine, the results demonstrated the high efficacy of colchicine, which, when added to standard treatment in patients with myocardial infarction, significantly reduces cardiovascular risk.